Acquiring Company
Scipher Medicine Corporation
Acquired Company
Chemomab Therapeutics Ltd
Waltham
Tel AvivBiotechnologyHealth CareMedicalTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Chemomab Therapeutics has entered into a definitive merger agreement with Scipher Medicine, valued at $150 million. The deal will see Chemomab equity holders owning approximately 32% of the combined entity, which will operate as Scipher Medicine Corporation. The merger is expected to close before the end of 2026, contingent on shareholder approvals and SEC review.
Don't miss Scipher Medicine Corporation's next move
Get an email the moment Scipher Medicine Corporation makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Chemomab Therapeutics Ltd?
Chemomab Therapeutics Ltd was acquired by Scipher Medicine Corporation, based in Waltham. The deal was reported on August 19, 2026. Scipher Medicine is a leader in transforming treatment through next-generation precision medicine. The company focuses on developing innovative approaches to treat autoimmune diseases. Scipher Medicine Corporation is privately held and operates in Biotechnology.
When did Scipher Medicine Corporation acquire Chemomab Therapeutics Ltd?
Scipher Medicine Corporation's acquisition of Chemomab Therapeutics Ltd was reported on August 19, 2026. Chemomab Therapeutics has entered into a definitive merger agreement with Scipher Medicine, valued at $150 million. The deal will see Chemomab equity holders owning approximately 32% of the combined entity, which will operate as Scipher Medicine Corporation. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Chemomab Therapeutics Ltd do?
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. It is publicly traded (CMMB), operating in Biotechnology, and is based in Tel Aviv.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.